Shandong Xinhua Pharmaceutical Co., Ltd

Hualu Network Group 中文版

Investor Relation

Information transparency and trust in peers

Investor Relation

INTERIM REPORT

Overseas Regulatory Announcement-Announcement on Finasteride Tablets of Subsidiary Having Obtained Drug Registration Certificate

Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 July 2025

Overseas Regulatory Announcement-Announcement on Having Obtained the Notification of Approval of Supplementary Drug Application and Other Relevant Information

Overseas Regulatory Announcement-Announcement on Having Obtained the Notification of Approval of Supplementary Drug Application and Other Relevant Information

Overseas Regulatory Announcement- Announcement on the Completion of Enrollment of the First Patient in China for Phase II Clinical Trials of OAB-14 Dry Suspension

Overseas Regulatory Announcement- Announcement on the Completion of Enrollment of the First Patient in China for Phase II Clinical Trials of OAB-14 Dry Suspension

Overseas Regulatory Announcement-Announcement on Sacubitril Valsartan Sodium Having Obtained the Notification of Approval of Marketing Application for Chemical Substance Drugs

Overseas Regulatory Announcement-Announcement on Sacubitril Valsartan Sodium Having Obtained the Notification of Approval of Marketing Application for Chemical Substance Drugs

Overseas Regulatory Announcement-Announcement on Ivabradine Hydrochloride Tablets Having Obtained Drug Registration Certificate

Overseas Regulatory Announcement-Announcement on Ivabradine Hydrochloride Tablets Having Obtained Drug Registration Certificate

Overseas Regulatory Announcement-Announcement on Ibuprofen Arginine Having Obtained the Notification of Approval of Marketing Application for Chemical Substance Drugs

Overseas Regulatory Announcement-Announcement on Ibuprofen Arginine Having Obtained the Notification of Approval of Marketing Application for Chemical Substance Drugs

Overseas Regulatory Announcement-Announcement on Having Obtained the Notification of Approval of Supplementary Drug Application and Other Relevant Information

Overseas Regulatory Announcement-Announcement on Having Obtained the Notification of Approval of Supplementary Drug Application and Other Relevant Information

Overseas Regulatory Announcement-Announcement on Isavuconazonium Sulfate for Injection Having Obtained Drug Registration Certificate

Overseas Regulatory Announcement-Announcement on Isavuconazonium Sulfate for Injection Having Obtained Drug Registration Certificate

Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 May 2025

Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 May 2025

总条数: 16条

＜ 1 2 ＞

跳转到: 页